

Figure 9-Statistical analysis.

A. Relative growth of LNCaP and CRPC cells C4-2 and 22Rv1, following 3-day treatment with MT 63-78 (MT), AR antagonist bicalutamide (Bic), and combined treatment (MT+Bic). Results are expressed as mean $\pm$ SD of three independent samples. One-way ANOVA test, followed by Tukey's post hoc test for multiple comparisons was performed and adjusted p values were calculated

LNCaP:

$$*** p= 3.18E-06 \text{ MT+ Bic 10uM vs MT}$$

$$*** p= 1.61E-07 \text{ MT+ Bic 20 uM vs MT}$$

$$*** p= 1.02E-08 \text{ MT+ Bic 40 uM vs MT}$$

$$### p= 1.24E-07 \text{ MT+ Bic 10uM vs Bic 10uM}$$

$$### p= 3.39E-07 \text{ MT+ Bic 20 uM vs Bic 20uM}$$

$$### p= 1.20E-05 \text{ MT+ Bic 40 uM vs Bic 40uM}$$

C4-2:

$$** p= 0.0041 \text{ MT+ Bic 20 uM vs MT}$$

$$*** p= 2.04E-06 \text{ MT+ Bic 40 uM vs MT}$$

$$### p= 1.83E-06 \text{ MT+ Bic 20 uM vs Bic 20 uM}$$

$$### p= 4.32E-06 \text{ MT+ Bic 40 uM vs Bic 40 uM}$$

22Rv1:

$$** p= 0.00516 \text{ MT+ Bic 20 uM vs MT}$$

$$*** p= 6.95E-06 \text{ MT+ Bic 40 uM vs MT}$$

$$## p= 0.002 \text{ MT+ Bic 20 uM vs Bic 20 uM}$$

$$## p= 0.002 \text{ MT+ Bic 40 uM vs Bic 40 uM}$$

B. Relative growth of LNCaP and CRPC cells C4-2 and 22Rv1, following 3-day treatment with MT 63-78 (MT), AR antagonist MDV3100 (MDV), and combined treatment (MT+MDV). Results are expressed as mean $\pm$ SD of three independent samples. One-way ANOVA test, followed by Tukey's post hoc test for multiple comparisons was performed and adjusted p values were calculated.

LNCaP:

$$*** p= 0.0001744 \text{ MT+ MDV 20uM vs MT}$$

$$*** p= 0.000153 \text{ MT+ MDV 40 uM vs MT}$$

$$### p= 4.53E-07 \text{ MT+ MDV 20 uM vs MDV 20uM}$$

$$### p= 0.0002 \text{ MT+ MT+ MDV 40 uM vs MDV 40uM}$$

C4-2:

 $p = 8.93E-06$ MT+ MDV 20uM *vs* MT

 $p = 4.78E-07$ MT+ MDV 40 uM *vs* MT

 $p = 1.23E-09$ MT+ MDV 20 uM *vs* MDV 20uM

 $p = 8.54E-06$ MT+ MT+ MDV 40 uM *vs* MDV 40uM

22Rv1:

 $p = 0.000286$ MT+ MDV 20uM *vs* MT

 $p = 5.51E-07$ MT+ MDV 40 uM *vs* MT

 $p = 6.88E-06$ MT+ MDV 20 uM *vs* MDV 20uM

 $p = 2.65E-06$ MT+ MT+ MDV 40 uM *vs* MDV 40uM

C. Relative growth of LNCaP and CRPC cells C4-2 and 22Rv1, following 3-day treatment with MT 63-78 (MT), CYP17A1 inhibitor abiraterone (Abi) and combined treatment (MT+Abi). Results are expressed as mean $\pm$ SD of three independent samples. One-way ANOVA test, followed by Tukey's post hoc test for multiple comparisons was performed and adjusted p values were calculated.

LNCaP:

 $p = 1.92E-07$ MT+ Abi *vs* MT

 $p = 1.17E-05$ MT+ Abi *vs* Abi

C4-2:

**
 $p = 0.0012$ MT+ Abi *vs* MT

 $p = 6.5E-11$ MT+ Abi *vs* Abi

22Rv1:

 $p = 0.00013$ MT+ Abi *vs* MT

 $p = 7.33E-06$ MT+ Abi *vs* Abi